vorinostat has been researched along with Dysplastic Nevus Syndrome, Hereditary in 2 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat is a small molecule inhibitor of class I and II histone deacetylases with preclinical activity in melanoma." | 9.19 | Phase II trial of vorinostat in advanced melanoma. ( Adams, PD; Alpaugh, RK; Haas, NB; Hotte, S; Litwin, S; Martin, LP; McBryan, T; McWhirter, E; Oza, A; Polintan, R; Quirt, I; vonMehren, M; Wang, L; Zweibel, J, 2014) |
| "Vorinostat is a small molecule inhibitor of class I and II histone deacetylases with preclinical activity in melanoma." | 5.19 | Phase II trial of vorinostat in advanced melanoma. ( Adams, PD; Alpaugh, RK; Haas, NB; Hotte, S; Litwin, S; Martin, LP; McBryan, T; McWhirter, E; Oza, A; Polintan, R; Quirt, I; vonMehren, M; Wang, L; Zweibel, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gassenmaier, M | 1 |
| Rentschler, M | 1 |
| Fehrenbacher, B | 1 |
| Eigentler, TK | 1 |
| Ikenberg, K | 1 |
| Kosnopfel, C | 1 |
| Sinnberg, T | 1 |
| Niessner, H | 1 |
| Bösmüller, H | 1 |
| Wagner, NB | 1 |
| Schaller, M | 1 |
| Garbe, C | 1 |
| Röcken, M | 1 |
| Haas, NB | 1 |
| Quirt, I | 1 |
| Hotte, S | 1 |
| McWhirter, E | 1 |
| Polintan, R | 1 |
| Litwin, S | 1 |
| Adams, PD | 1 |
| McBryan, T | 1 |
| Wang, L | 1 |
| Martin, LP | 1 |
| vonMehren, M | 1 |
| Alpaugh, RK | 1 |
| Zweibel, J | 1 |
| Oza, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Vorinostat in Patients With Advanced Melanoma[NCT00121225] | Phase 2 | 32 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Blood specimens were collected from participants on Day 1 Cycle 1 prior to treatment (baseline), Day 1 3-4 hours following Vorinostat ingestion, Day 8 and Day 15. VEGF serum concentrations were detected using the Luminex multiplexed assay, where the median fluorescence intensity results were analyzed by a weighted five-parameter logistic method. The values were averaged across all time points per participant. (NCT00121225)
Timeframe: Baseline, Day 1, Day 8 and Day 15
| Intervention | pg (Mean) |
|---|---|
| Arm 1 Vorinostat | 203 |
Per Response Evaluation Criteria in Solid Tumours Criteria (RECIST v1.0) for target lesions and are assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least 30% decrease in sum of longest diameter of target lesions; Objective Response (OR) = CR+ PR. (NCT00121225)
Timeframe: Up to 5 years
| Intervention | participants (Number) |
|---|---|
| Arm I | 2 |
(NCT00121225)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm 1 Vorinostat | 4 |
Macro H2A and HP1 expression levels were compared through analysis of log fold changes in antibody expression in a multivariate general linear model between progressive disease and stable disease outcomes. (NCT00121225)
Timeframe: Baseline and day 15
| Intervention | log fold change (Mean) | ||
|---|---|---|---|
| MacroH2A1.1 | MacroH2A1.2 | HP1 | |
| Arm 1 Vorinostat | 0.149 | -0.748 | -0.077 |
Participants were assessed for p53 allelic variation at baseline (NCT00121225)
Timeframe: Baseline
| Intervention | participants (Number) | |
|---|---|---|
| Wild Type | Mutant | |
| Arm 1 Vorinostat | 20 | 11 |
1 trial available for vorinostat and Dysplastic Nevus Syndrome, Hereditary
| Article | Year |
|---|---|
Phase II trial of vorinostat in advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Disease-Free Survival; Female; Fi | 2014 |
1 other study available for vorinostat and Dysplastic Nevus Syndrome, Hereditary
| Article | Year |
|---|---|
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors.
Topics: Cell Line, Tumor; Cell Proliferation; DNA; Histone Deacetylase Inhibitors; Humans; Melanocytes; Mela | 2020 |